CLYBL-AS2: A Potential Drug Target and Biomarker (G100874063)

Target Name: CLYBL-AS2

NCBI ID: G100874063

CLYBL-AS2

Other Name(s): CLYBL antisense RNA 2

CLYBL-AS2: A Potential Drug Target and Biomarker

CLYBL-AS2, also known as CSF-1, is a protein that is expressed in the central nervous system (CNS) and has been shown to play a role in various neurological disorders, including epilepsy, schizophrenia, and multiple sclerosis. The protein is derived from the interleukin-2 (IL-2) receptor, which is a protein that is expressed in various tissues throughout the body, including the CNS.

IL-2 is a cytokine that is involved in the regulation of immune and inflammatory responses. It is expressed in various tissues, including the CNS, and has been shown to play a role in the development and progression of various neurological disorders. The exact mechanism by which IL-2 contributes to neurological disorders is not fully understood, but it is thought to participate in the regulation of neurotransmitter signaling, inflammation, and immune responses.

CLYBL-AS2 is a 21-kDa protein that is expressed in the CNS and is derived from the IL-2 receptor. It is composed of a 156 amino acid chain and has a calculated molecular mass of 19,112. The protein has a molecular diameter of 12.5 nm and a calculated pI of 9.9. It is expressed in various tissues, including the brain, spleen, heart, and liver.

CLYBL-AS2 has been shown to play a role in the regulation of neurotransmitter signaling in the CNS. It has been shown to interact with various neurotransmitter receptors, including dopamine, serotonin, and GABA. The exact mechanism by which CLYBL-AS2 interacts with these neurotransmitter receptors is not fully understood, but it is thought to participate in the regulation of neurotransmitter signaling by modulating the activity of these receptors.

CLYBL-AS2 has also been shown to play a role in the regulation of inflammation in the CNS. It has been shown to interact with various immune cells, including T cells and microglia. The exact mechanism by which CLYBL-AS2 interacts with these immune cells is not fully understood, but it is thought to participate in the regulation of immune responses by modulating the activity of these immune cells.

CLYBL-AS2 has been shown to be involved in the development and progression of various neurological disorders, including epilepsy, schizophrenia, and multiple sclerosis. It is thought to participate in the regulation of neurotransmitter signaling, inflammation, and immune responses, which are involved in the development and progression of these disorders.

In conclusion, CLYBL-AS2 is a protein that is derived from the IL-2 receptor and is expressed in various tissues, including the CNS. It has been shown to play a role in the regulation of neurotransmitter signaling, inflammation, and immune responses, which are involved in the development and progression of various neurological disorders. Further research is needed to fully understand the role of CLYBL-AS2 in neurological disorders.

Protein Name: CLYBL Antisense RNA 2

The "CLYBL-AS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLYBL-AS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets